mochi glp-1 MY NEW PROVIDER IS..... HEALTH; GLP-1 JOURNEY AGAIN, HOW TO GET GLP-1 SUPPORT My Honest Experience with Mochi

Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation

I would love to see what the out of pocket cost for patients are

Senate Committee on Health, Education, Labor, and Pensions (HELP) hearing noted that Ozempic costs over 15 times more in the United States than in Germany), but still not necessarily affordable

Phase 2 trial: up to 24.2% weight loss at 48 weeks

10.3390/ijms18081649 25

Liu M, Guo S, Li X, et al